Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | SOD1 | P00441 | 1/20 | 0.49 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2137838 | 0.90 | MRGPRX4 (0.69) | MRGPRX4NR4A2MAOBHDAC4NAAA | |
| SCHEMBL379281 | 0.88 | MAOB (0.67) | MRGPRX4NR4A2MAOBCYP4F2CYP4A11 | |
| SCHEMBL16346074 | 0.85 | GSTP1 (0.66) | MRGPRX4NR4A2MAOBHDAC4NAAA | |
| SCHEMBL27707562 | 0.84 | MRGPRX4 (0.52) | MRGPRX4NR4A2MAOBHDAC4NAAA | |
| SCHEMBL7346174 | 0.82 | MRGPRX4 (0.64) | MRGPRX4NR4A2MAOBHDAC4NAAA | |
| SCHEMBL2265075 | 0.81 | MAOB (0.58) | NR4A2MAOBCYP4F2CYP4A11BCHE | |
| SCHEMBL2570119 | 0.81 | MAOB (0.65) | MRGPRX4NR4A2MAOBHDAC4NAAA | |
| SCHEMBL30426715 | 0.81 | MAOB (0.68) | MRGPRX4NR4A2MAOBHDAC4NAAA | |
| SCHEMBL1956583 | 0.81 | MRGPRX4 (0.58) | MRGPRX4NR4A2MAOBHDAC4NAAA | |
| SCHEMBL3786472 | 0.81 | MAOB (0.68) | MRGPRX4NR4A2MAOBHDAC4NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765054-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-09-19 | — | — | US | claimed |
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation (US) | 2014-06-12 | — | — | US | claimed |
| EP-2667709-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2013-12-04 | — | — | EP | claimed |
| WO-2012103008-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2012-08-02 | — | — | WO | claimed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | claimed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | claimed |
| CN-110194743-B | Phenyl (3-methoxy-4- (4-methyl-1H-imidazole-1-yl) phenyl) ketone compound | 云南大学 | 2022-11-11 | — | — | CN | disclosed |
| US-9765054-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2667709-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012103008-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. (US) | 2012-08-02 | — | — | WO | disclosed |
| US-6166072-A | Amino acid derivatives | ALLELIX NEUROSCIENCE, INC. (CA) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | MRGPRX4 1051/4885NR4A2 4607/4885MAOB 109/4885 |
| US-20140163009-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | MRGPRX4 4318/4885NR4A2 3028/4885MAOB 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.